Collegium Pharmaceutical to Acquire AZSTARYS for $650M, Expanding ADHD Portfolio and Boosting Growth

summarizeSummary

Collegium Pharmaceutical announced a definitive agreement to acquire AZSTARYS for $650 million in cash and up to $135 million in milestones, significantly expanding its ADHD portfolio and expected to be immediately accretive to adjusted EBITDA.

check_boxKey Events

• Acquisition Agreement

  Collegium Pharmaceutical entered into an Equity Purchase Agreement to acquire AZSTARYS, a central nervous system stimulant prescription medicine for ADHD, from Corium Therapeutics Holdings, LLC and Corium, LLC.

• Transaction Value

  The acquisition is for $650 million in cash at closing, with potential additional milestone payments of up to $135 million based on future commercial and regulatory achievements.

• Strategic Rationale

  The acquisition strengthens Collegium's position in the ADHD market, further diversifying its commercial portfolio, and is expected to be immediately accretive to adjusted EBITDA.

• Financial Impact

  AZSTARYS is projected to generate over $50 million in pro forma net revenue in the second half of 2026 and is supported by six Orange Book-listed patents, most of which do not expire until December 2037.

auto_awesomeAnalysis

This 8-K filing details Collegium Pharmaceutical's definitive agreement to acquire AZSTARYS, an ADHD treatment, for $650 million in cash plus up to $135 million in potential milestone payments. This is a highly significant acquisition, representing over 50% of the company's current market capitalization. The company anticipates the acquisition will be immediately accretive to adjusted EBITDA, generate over $50 million in pro forma net revenue in the second half of 2026, and extend patent protection for its ADHD portfolio until 2037. The deal is funded by existing cash and a new $300 million delayed draw term loan, with expected net leverage of approximately 2x post-closing. This strategic move aims to strengthen Collegium's position in the ADHD market and accelerate its growth trajectory. Investors should monitor the successful integration of AZSTARYS and its contribution to future financial performance.